Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis
凋亡肺细胞衍生的氧化磷脂驱动巨噬细胞激活并引发肺纤维化
基本信息
- 批准号:10470837
- 负责人:
- 金额:$ 61.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAlveolarAlveolar MacrophagesAlveolar fibrosisAnimal ModelApoptosisApoptoticAttenuatedAutomobile DrivingBleomycinBone MarrowBone Marrow TransplantationCCL2 geneCD36 geneCatabolismCellsCessation of lifeChimera organismChronicCicatrixDataDefectDevelopmentDiagnosisDiseaseDisease ProgressionDisease modelEnzymesEpithelialEpithelial CellsEtiologyExhibitsExposure toFibroblastsFibrosisGenerationsGoalsHumanImpairmentIn VitroIngestionInjuryKnockout MiceKnowledgeLeadLigandsLinkLipidsLungMacrophage ActivationMediatingMedicalModelingMusNull LymphocytesOrganOrgan failureOxidative StressOxidesPathogenesisPathologyPathway interactionsPhenotypePhospholipase A2PhospholipidsProfibrotic signalPublishingPulmonary FibrosisRecombinant ProteinsRecombinantsReportingResearch Project GrantsRoleSamplingSecondary toShortness of BreathSignal PathwaySignal TransductionSystemic diseaseTestingTimeTransforming Growth Factor betaTransgenic MiceTranslatingTransplantation Chimeraalveolar epitheliumcell injurychemokineexperimental studyfibrotic lungfibrotic lung diseaseidiopathic pulmonary fibrosisin vivoinhibitorinjuredinterstitiallung injurymacrophagemonocytemouse modelnew therapeutic targetnovelnovel therapeuticsoxidationpneumocytereceptorrecruitrepairedresponsesurfactanttargeted treatmenttissue injuryuptake
项目摘要
Project Summary
Progressive lung fibrosis is a feature of systemic diseases and chronic injury but can also occur in the
absence of any known etiology as with Idiopathic Pulmonary Fibrosis (IPF). IPF is a devastating disorder with a
median survival of ~4 years from time of diagnosis and current medical therapy only modestly slows disease
progression. Even fibrosis from known causes can lead to a difficult progressive course, thsu it is vital that the
pathogenesis of fibrosis is more precisely elucidated in order to identify novel therapeutic targets.
Recent studies from both human fibrotic diseases and animal models have identified a critical role for type II
alveolar epithelial cell (AEC2) injury and apoptosis in the initiation of interstitial scarring. However, the
downstream pathways that translate AEC2 injury/death into fibrosis remain undefined. Our preliminary data
demonstrate that an array of AEC2 insults drives their expression of CCL2/CCL12, chemokines involved in
pro-fibrotic monocyte/macrophage recruitment. The importance of this response was confirmed by
demonstrating that mice deficient in AEC2-derived CCL12 developed attenuated fibrosis in a murine model.
AEC2 injury can also progress to apoptosis with an accompanying oxidation of their abundant phospholipid
stores, and we discovered that uptake and accumulation of oxidized phospholipid (oxPL) derived from
apoptotic AEC2s (either released or retained within apoptotic bodies) induces a pro-fibrotic phenotypic switch
in the ingesting lung macrophage. Administration of apoptotic AEC2s or oxPL into the lungs of uninjured mice
is sufficient to drive lung fibrosis and this uptake is mediated by CD36. The accumulation of oxPL within
macrophages is also determined by its catabolism which we have shown is regulated primarily by lysosomal
phospholipase A2 (LPLA2). Our preliminary results indicate that the rapid intracellular degradation of oxPL by
LPLA2 in alveolar macrophages can minimize macrophage activation. Compared to resident macrophages,
monocyte-derived macrophages that are recruited to the injured lung exhibit a greater pro-fibrotic response to
oxPL accumulation due to their decreases expression of LPLA2.
These preliminary data motivate our central hypothesis that AEC2 injury/apoptosis results in a coordinated
response in which the elaboration of CCL12 from injured AECs attracts monocyte-derived macrophages to the
alveolar space where they engulf and accumulate oxPL resulting in robust pro-fibrotic activation. We will
pursue a multifaceted approach using in vitro studies of primary murine and human macrophages with in vivo
mouse experiments using novel transgenic mice, bone marrow transplant chimeras, and complementary
models of lung fibrosis. We have formed a synergistic team with expertise in lipids, monocyte/macrophages,
and AEC2s. Our research project specifically addresses a recognized knowledge gap in fibrosis pathogenesis.
Importantly, the results of these studies will define previously unexplored mechanisms that critically regulate
fibrosis and will inform the development of novel therapies.
项目摘要
进行性肺纤维化是全身性疾病和慢性损伤的特征,但也可能发生
没有任何已知病因,即特发性肺纤维化(IPF)。 IPF是一种毁灭性疾病,有
自诊断和当前医疗疗法从诊断和当前的医疗疗法开始的中位生存期仅减慢疾病
进展。即使是来自已知原因的纤维化也可能导致艰难的进步过程,这一点至关重要
为了鉴定新的治疗靶标,纤维化的发病机理更精确地阐明。
来自人类纤维化疾病和动物模型的最新研究已经确定了II型的关键作用
肺泡上皮细胞(AEC2)损伤和凋亡的开始。但是,
将AEC2损伤/死亡转化为纤维化的下游途径仍然不确定。我们的初步数据
证明AEC2的一系列侮辱驱动其表达CCL2/CCL12,趋化因子涉及
促纤维细胞/巨噬细胞募集。该回应的重要性已得到证实
证明缺乏AEC2衍生的CCL12的小鼠在鼠模型中会导致纤维化减弱。
AEC2损伤也可以通过伴随其丰富磷脂的氧化而发展为凋亡
商店,我们发现源自氧化磷脂(OXPL)的吸收和积累
凋亡AEC2S(释放或保留在凋亡体内)会诱导促纤维化表型开关
在摄入的肺巨噬细胞中。将凋亡AEC2S或OXPL施用到未受伤的小鼠的肺中
足以驱动肺纤维化,这种摄取是由CD36介导的。 OXPL在
巨噬细胞还取决于其分解代谢,我们表明的主要由溶酶体调节
磷脂酶A2(LPLA2)。我们的初步结果表明,OXPL的细胞内降解快速
肺泡巨噬细胞中的LPLA2可以最大程度地减少巨噬细胞的激活。与常驻巨噬细胞相比
募集到受伤的肺部的单核细胞衍生的巨噬细胞表现出更大的促纤维化反应
OXPL由于其降低LPLA2的表达而产生的。
这些初步数据激发了我们的中心假设,即AEC2损伤/凋亡导致协调
在受伤的AEC中阐述CCL12的反应吸引了单核细胞衍生的巨噬细胞
它们吞噬并积累OXPL的肺泡空间,导致稳健的促纤维激活。我们将
使用体内原代鼠和人类巨噬细胞的体外研究采用多方面的方法
使用新型转基因小鼠,骨髓移植嵌合体和互补的小鼠实验
肺纤维化模型。我们组成了一个协同的团队,具有脂质,单核细胞/巨噬细胞的专业知识,
和AEC2S。我们的研究项目专门解决了纤维化发病机理中公认的知识差距。
重要的是,这些研究的结果将定义以前未开发的机制,这些机制严格调节
纤维化并将告知新型疗法的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN KEEWOUN KIM其他文献
KEVIN KEEWOUN KIM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN KEEWOUN KIM', 18)}}的其他基金
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis
凋亡肺细胞衍生的氧化磷脂驱动巨噬细胞激活并引发肺纤维化
- 批准号:
10293745 - 财政年份:2021
- 资助金额:
$ 61.7万 - 项目类别:
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis
凋亡肺细胞衍生的氧化磷脂驱动巨噬细胞激活并引发肺纤维化
- 批准号:
10616814 - 财政年份:2021
- 资助金额:
$ 61.7万 - 项目类别:
Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis
靶向成纤维细胞盘状结构域受体 2 用于肺纤维化免疫治疗
- 批准号:
10532241 - 财政年份:2021
- 资助金额:
$ 61.7万 - 项目类别:
Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis
靶向成纤维细胞盘状结构域受体 2 用于肺纤维化免疫治疗
- 批准号:
10362183 - 财政年份:2021
- 资助金额:
$ 61.7万 - 项目类别:
Function of epithelial-mesenchymal transition during pulmonary fibrosis
上皮间质转化在肺纤维化过程中的作用
- 批准号:
8821656 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
Function of epithelial-mesenchymal transition during pulmonary fibrosis
上皮间质转化在肺纤维化过程中的作用
- 批准号:
8646991 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
Type I collagen signaling in lung injury and fibrosis
肺损伤和纤维化中的 I 型胶原信号传导
- 批准号:
9308528 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
Type I collagen signaling in lung injury and fibrosis
肺损伤和纤维化中的 I 型胶原信号传导
- 批准号:
9898421 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
Function of epithelial-mesenchymal transition during pulmonary fibrosis
上皮间质转化在肺纤维化过程中的作用
- 批准号:
8290684 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
Function of epithelial-mesenchymal transition during pulmonary fibrosis
上皮间质转化在肺纤维化过程中的作用
- 批准号:
8469897 - 财政年份:2012
- 资助金额:
$ 61.7万 - 项目类别:
相似国自然基金
螺旋层状结构的矿化纤维素纳米晶材料的仿生构建及其促牙槽骨组织再生的机制研究
- 批准号:82301152
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
牙周膜细胞通过CXCL1-CXCR2轴调控巨噬细胞极化在正畸牙槽骨改建中的作用研究
- 批准号:82301115
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
长效抑炎修复材料通过诱导巨噬细胞极化促进牙槽骨再生研究
- 批准号:32301129
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Sparcl1调控Myh11+干细胞促进牙槽骨修复再生的机制研究
- 批准号:82370945
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
三维预血管化磷酸钙骨水泥牙槽骨组织工程支架的构建及三维共培养成血管相关机制的研究
- 批准号:82301117
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Macrophage metabolism in diabetes and tuberculosis comorbidity
糖尿病和结核病合并症中的巨噬细胞代谢
- 批准号:
10645801 - 财政年份:2023
- 资助金额:
$ 61.7万 - 项目类别:
Modulation of epigenetic programming of tissue resident macrophage lineages to impact HIV-1 infection, maintenance, and persistence.
调节组织驻留巨噬细胞谱系的表观遗传编程以影响 HIV-1 感染、维持和持久性。
- 批准号:
10675934 - 财政年份:2023
- 资助金额:
$ 61.7万 - 项目类别:
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 61.7万 - 项目类别:
The role of pathogen-experienced macrophage subsets in mediating lung immunity and heterologous protection
经历病原体的巨噬细胞亚群在介导肺免疫和异源保护中的作用
- 批准号:
10753773 - 财政年份:2023
- 资助金额:
$ 61.7万 - 项目类别:
Heterogeneity and cellular hierarchy of lung cDC2
肺 cDC2 的异质性和细胞层次
- 批准号:
10665348 - 财政年份:2023
- 资助金额:
$ 61.7万 - 项目类别: